Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Participants found to be human leukocyte antigen (HLA)-DPB1*04:01 positive and whose tumors
are MAGE-A3 and/or MAGE-A6 positive can participate if all eligibility criteria are met.
Other tests required to determine eligibility include a physical exam, electrocardiogram
(ECG) and echocardiogram (ECHO) of the heart, CT or MRI scans, and blood draws. Eligible
participants have white blood cells collected by leukapheresis. These cells are genetically
modified to make the experimental treatment KITE-718. The desired outcome is that the
genetically modified T cells will target tumor cells that express MAGE-A3 and/or MAGE-A6,
which are proteins that can be expressed by cancer cells. Participants receive chemotherapy
prior to the KITE-718 infusion. After the KITE-718 infusion, participants will be followed
for side effects and have scans performed to see any potential impact on their cancers. Study
procedures may be performed while hospitalized and/or in the outpatient setting.

Key Inclusion Criteria:

- Age ≥ 18 years

- Relapsed or refractory disease after a systemic standard of care treatment regimen
and, if available, at least one standard of care salvage regimen

- MAGE-A3/A6 positive tumor

- HLA-DPB1*04:01 positive

- At least 1 measurable lesion on CT or MRI

- No evidence of central nervous system (CNS) disease by MRI or CT of the brain. Note:
Prior brain metastasis which have been treated with definitive therapy are eligible.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Toxicities due to prior therapy must be recovered to baseline or ≤ grade 1, except for
clinically non-significant toxicities such as alopecia

- Adequate bone marrow function as evidenced by:

- Absolute neutrophil count (ANC) ≥ 1000/mm^3

- Platelet ≥ 100/mm^3

- Hemoglobin > 8 g/dL

- Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

- Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 cc/min

- Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 x upper limit
normal (ULN) or ≤ 5 x ULN if documented liver metastases

- Total bilirubin ≤ 1.5 mg/dL

- Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as
determined by an ECHO, and no clinically significant ECG findings

- No clinically significant pleural effusion

- Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria:

- Malignancy other than non-melanoma skin cancer, carcinoma in situ, or low grade
prostate cancer for which watch-and-wait approach is standard of care, unless disease
free for at least 3 years

- Clinically significant cardiac disease within last 12 months

- Stroke or transient ischemic attack (TIA) within 12 last months

- Symptomatic deep vein thrombosis or pulmonary embolism within last 6 months

- Prior MAGE-A3/A6-targeting therapy

- Live vaccine ≤ 4 weeks prior to enrollment

- Systemic corticosteroid therapy within 7 days before enrollment.

- History of severe, immediate hypersensitivity reaction attributed to aminoglycosides

- Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials
for management.

- Presence of any indwelling line or drain. Note: Dedicated central venous access
catheters such as a Port-a-Cath are permitted.

- Primary immunodeficiency

- Autoimmune disease resulting in end-organ injury or requiring systemic
immunosuppression/systemic disease modifying agents within the last 2 years prior to
enrollment

- Known history of infection with HIV, hepatitis B (HBsAg positive), or hepatitis C
(anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if
the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or
nucleic acid testing.

- Females who are pregnant as confirmed by a positive serum or urine pregnancy test or
are breastfeeding.

- Individuals of both genders of child-bearing potential who are not willing to practice
birth control from the time of consent through 6 months after the completion of
KITE-718

Note: Other protocol defined Inclusion/Exclusion criteria may apply.